These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15500374)

  • 1. The role of growth hormone-receptor antagonism in relation to acromegaly.
    Ayuk J; Sheppard MC
    Expert Opin Pharmacother; 2004 Nov; 5(11):2279-85. PubMed ID: 15500374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pegvisomant in the treatment of acromegaly.
    Roelfsema F; Biermasz NR; Pereira AM; Romijn JA
    Expert Opin Biol Ther; 2008 May; 8(5):691-704. PubMed ID: 18407771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Growth hormone receptor antagonist in the treatment of acromegaly].
    Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
    Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
    Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H; Shimatsu A; Okayama A; Sato T
    Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
    Paisley AN; Trainer P; Drake W
    Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the treatment of acromegaly].
    Krysiak R; Okopień B; Marek B
    Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with pegvisomant in the treatment of acromegaly.
    Drake WM
    Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
    Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegvisomant: an advance in clinical efficacy in acromegaly.
    Stewart PM
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic effects of GH antagonism in patients with acromegaly.
    Trainer PJ
    Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S152-6. PubMed ID: 12914745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegvisomant: current and potential novel therapeutic applications.
    Thankamony GN; Dunger DB; Acerini CL
    Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
    Tritos NA; Biller BM
    Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapy and drug pipeline for the treatment of patients with acromegaly.
    Kumar SS; Ayuk J; Murray RD
    Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment in acromegaly.
    Paisley AN; Trainer PJ
    Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
    Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of pegvisomant in patients with acromegaly.
    Hodish I; Barkan A
    Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):324-32. PubMed ID: 18431372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.